Prostate cancer screening with prostate-specific antigen: A guide to the guidelines

2015, Cancer in Australia 2014: actual incidence data from 1982 to 2011 and mortality data from 1982 to 2012 with projections to 2014, Asia Pac J Clin Oncol, 11, 208, 10.1111/ajco.12407 Prostate Cancer Statistics: Australian Institute of Health and Welfare; 2015 [Internet]. [cited 2016 Feb 24]. Available from: https://prostate-cancer.canceraustralia.gov.au/statistics. Australian Institute of Health and Welfare, 2014 McGrath, 2016, Prostate cancer biomarkers: are we hitting the mark?, Prostate Int, 4, 130, 10.1016/j.prnil.2016.07.002 Perera, 2016, Management of men with previous negative prostate biopsy, Curr Opin Urol, 26, 481, 10.1097/MOU.0000000000000315 Yassaie, 2016, Primary care follow-up of radical prostatectomy patients: a regional New Zealand experience, Prostate Int, 4, 136, 10.1016/j.prnil.2016.07.003 Devlin, 2004, Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis, Health Econ, 13, 437, 10.1002/hec.864 Roobol, 2003, Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands), BJU Int, 92, 48, 10.1111/j.1464-410X.2003.04390.x Britt, 2010 Let sleeping dogs lie?, 2011, What men should know before getting tested for prostate cancer, Aust NZ J Public Health, 35, 96, 10.1111/j.1753-6405.2010.00675.x Australian Institute of Health and Welfare, 2013 Lo, 2016, Australian patterns of prostate cancer care: are they evolving, Prostate Int, 4, 20, 10.1016/j.prnil.2015.11.001 Bartsch, 2001, Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria, Urology, 58, 417, 10.1016/S0090-4295(01)01264-X van der Cruijsen-Koeter, 2005, Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam, J Urol, 174, 121 Schröder, 2014, Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, Lancet, 384, 2027, 10.1016/S0140-6736(14)60525-0 Holmberg, 2012, Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting, J Natl Cancer Inst Monogr, 2012, 230, 10.1093/jncimonographs/lgs025 Bill-Axelson, 2014, Radical prostatectomy or watchful waiting in early prostate cancer, New Engl J Med, 370, 932, 10.1056/NEJMoa1311593 Wilt, 2012, Radical prostatectomy versus observation for localized prostate cancer, New Engl J Med, 367, 203, 10.1056/NEJMoa1113162 Roehl, 2006, Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results, Urol Oncol, 24, 465, 10.1016/j.urolonc.2005.11.039 Walsh, 2000, Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates, J Urol, 163, 364 Merrill, 2000, Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening, J Urol, 163, 503 Welch, 2015, Trends in metastatic breast and prostate cancer—lessons in cancer dynamics, New Engl J Med, 373, 1685, 10.1056/NEJMp1510443 Barry, 2009, Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?, J Natl Cancer Inst, 101, 362, 10.1093/jnci/djp028 Draisma, 2009, Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context, J Natl Cancer Inst, 101, 374, 10.1093/jnci/djp001 Arnsrud Godtman, 2015, Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial, Eur Urol, 68, 354, 10.1016/j.eururo.2014.12.006 Roobol, 2013, Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer, Eur Urol, 64, 530, 10.1016/j.eururo.2013.05.030 Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al., eds. SEER Cancer Statistics Review, 1975–2005 [Internet]. Bethesda (MD): National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2005/. Andriole, 2009, Mortality results from a randomized prostate-cancer screening trial, New Engl J Med, 360, 1310, 10.1056/NEJMoa0810696 Yaxley, 2013, Prostate cancer - active surveillance as a management option, Aust Fam Physician, 42, 74 National Health and Medical Research Council. Prostate-specific antigen (PSA) testing in asymptomatic men 2014 [Internet]. [cited 2015 Sep 30]. Available from: https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/men4d_psa_testing_asymptomatic_men_140304.pdf. Medew, 2015 2011 Cancer Council Australia. Cancer Guidelines Wiki. Clinical practice guidelines PSA testing and early management of test-detected prostate cancer [Internet]. [cited 2016 15 Feb]. Available from: http://wiki.cancer.org.au/australia/Guidelines:PSA_Testing. 2016 2015 2015 Mottet, 2015 Loeb, 2012, Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer, BJU Int, 109, 508, 10.1111/j.1464-410X.2011.10900.x Oefelein, 2000, Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making, Urology, 56, 1021, 10.1016/S0090-4295(00)00793-7